Incannex Healthcare (IXHL) Long-Term Investments (2020 - 2026)

Incannex Healthcare (IXHL) posted Long-Term Investments of $27000.0 for Q1 2026, down 52.63% sequentially from $57000.0 in Q4 2025.

Incannex Healthcare (IXHL) Long-Term Investments (2020 - 2026) Analysis & Trends

Incannex Healthcare has reported Long-Term Investments for 3 years, with the latest figure at $27000.0 in Q1 2026.

Quarterly Long-Term Investments changed N/A year-over-year to $27000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27000.0 (changed N/A YoY) and the FY2020 annual result came in at $29277.0, changed N/A from the prior year.
Long-Term Investments fell to $27000.0 in Q1 2026 per IXHL's latest filing, from $57000.0 in the prior quarter.
Over five years, Long-Term Investments peaked at $57000.0 in Q4 2025 and troughed at $27000.0 in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-	92.58 Mn
2	Teva Pharmaceutical Industries	42.95 Bn	39.30 Bn	2.15 Bn	-
3	Zoetis	31.58 Bn	29.90 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	63.23 Mn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn	1.14 Bn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.53 Bn	15.14 Bn	935.80 Mn	149.10 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-	60.00 Mn
10	Incannex Healthcare	41.74 Mn	41.74 Mn	-	27,000.00

Download Data